✦ LIBER ✦

Prolonging platinum-based therapy for advanced NSCLC not justified

Book ID: 120845086
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 2007
Weight: 121 KB
Volume: &NA;
Category: Article
ISSN: 1173-8324
DOI: 10.2165/00128413-200716170-00027

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

E37. Non-platinum regimens for advanced

E37. Non-platinum regimens for advanced disease: Patient selection based on subhistologies of NSCLC

✍ Kosmidis, Paris A. 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 33 KB

Advanced age alone does not compromise o

Advanced age alone does not compromise outcome in fit non-small cell lung cancer (NSCLC) patients (pts) receiving platinum (DDP)-based therapy (Tx): Implications of ECOG 5592

✍ Langer, C; Manola, J; Bernardo, P; Bonomi, P; Kugler, A; Johnson, D 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 117 KB

European perspectives on paclitaxel/plat

European perspectives on paclitaxel/platinum-based therapy for advanced non-Small cell lung cancer

✍ Silvia Novello; Thierry Le Chevalier 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 822 KB

Cisplatin based chemotherapy with accele

Cisplatin based chemotherapy with accelerated, B.I.D. radiation therapy for advanced non-small cell lung cancer (NSCLC)

📂 Article 📅 1990 🏛 Elsevier Science 🌐 English ⚖ 146 KB

P-37 Activity of carboplatin in patients

P-37 Activity of carboplatin in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy but not platinum based

✍ Fernández, Yolanda; Esteban, Emilio; Fra, Joaquin; Mun˜iz, Isabel; Palacio, Isab 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 194 KB

Gemcitabine plus epirubicin in patients

Gemcitabine plus epirubicin in patients with advanced urothelial carcinoma who are not eligible for platinum-based regimens

✍ Sergio Ricci; Luca Galli; Aldo Chioni; Mauro Iannopollo; Andrea Antonuzzo; Franc 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 84 KB

## Abstract ## BACKGROUND The objective of this study was to evaluate the efficacy and toxicity of gemcitabine plus epirubicin in previously untreated patients with advanced urothelial carcinoma who were not eligible for cisplatin‐based regimens. ## METHODS Patients with advanced urothelial carc